SAN DIEGO: Aethlon Medical, Inc. (OTCBB:AEMD) has announced that the first patient enrolled in the Company's FDA approved feasibility study has completed their full Hemopurifier® treatment protocol without any device-related adverse events. The study protocol, which is being administered at DaVita Med Center Dialysis in Houston, is enrolling ten chronic dialysis patients infected with Hepatitis C virus (HCV) to receive a six treatment protocol of Hemopurifier therapy. The Aethlon Hemopurifier is a first-in-class bio-filtration device that provides the broad-spectrum elimination of infectious viruses from the circulatory system of infected individuals.
- THE EDITORIAL TEAM
- Health Security
- Posted On



